Literature DB >> 24232411

Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.

Scott D Grosse1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24232411      PMCID： PMC4454889          DOI： 10.1038/gim.2013.158

Source DB:  PubMed          Journal:  Genet Med        ISSN： 1098-3600            Impact factor:   8.822


× No keyword cloud information.
  21 in total

Review 1.  Challenges of translating genetic tests into clinical and public health practice.

Authors:  Wolf H Rogowski; Scott D Grosse; Muin J Khoury
Journal:  Nat Rev Genet       Date:  2009-07       Impact factor: 53.242

2.  A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.

Authors:  Lisa M Meckley; James M Gudgeon; Jeffrey L Anderson; Marc S Williams; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.

Authors:  John F P Bridges; Eberechukwu Onukwugha; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

5.  Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

Authors:  J H S You; K K N Tsui; R S M Wong; G Cheng
Journal:  Clin Pharmacol Ther       Date:  2009-07-01       Impact factor: 6.875

6.  Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database.

Authors:  P C Adams; J C Gregor; A E Kertesz; L S Valberg
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

7.  Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Authors:  Mark H Eckman; Jonathan Rosand; Steven M Greenberg; Brian F Gage
Journal:  Ann Intern Med       Date:  2009-01-20       Impact factor: 25.391

8.  A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

Authors:  David L Veenstra; Joshua A Roth; Louis P Garrison; Scott D Ramsey; Wylie Burke
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

9.  Modeling uncertain outcomes of genetic testing: factor V Leiden mutation and pregnant women.

Authors:  Scott D Grosse; Aaron B Caughey
Journal:  Genet Med       Date:  2013-02-28       Impact factor: 8.822

10.  A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.

Authors:  Preeti S Bajaj; David L Veenstra
Journal:  Genet Med       Date:  2012-11-08       Impact factor: 8.822
View more
  11 in total

1.  'Someday it will be the norm': physician perspectives on the utility of genome sequencing for patient care in the MedSeq Project.

Authors:  Jason L Vassy; Kurt D Christensen; Melody J Slashinski; Denise M Lautenbach; Sridharan Raghavan; Jill Oliver Robinson; Jennifer Blumenthal-Barby; Lindsay Zausmer Feuerman; Lisa Soleymani Lehmann; Michael F Murray; Robert C Green; Amy L McGuire
Journal:  Per Med       Date:  2015       Impact factor: 2.512

2.  The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.

Authors:  Scott D Grosse; John D Thompson; Yao Ding; Michael Glass
Journal:  Milbank Q       Date:  2016-06       Impact factor: 4.911

3.  The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial.

Authors:  Jason L Vassy; Kurt D Christensen; Erica F Schonman; Carrie L Blout; Jill O Robinson; Joel B Krier; Pamela M Diamond; Matthew Lebo; Kalotina Machini; Danielle R Azzariti; Dmitry Dukhovny; David W Bates; Calum A MacRae; Michael F Murray; Heidi L Rehm; Amy L McGuire; Robert C Green
Journal:  Ann Intern Med       Date:  2017-06-27       Impact factor: 25.391

Review 4.  A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system.

Authors:  Christine Y Lu; Marc S Williams; Geoffrey S Ginsburg; Sengwee Toh; Jeff S Brown; Muin J Khoury
Journal:  Genet Med       Date:  2017-08-10       Impact factor: 8.822

5.  When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-09-24

6.  Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement.

Authors:  Joshua P Cohen; Abigail E Felix
Journal:  J Pers Med       Date:  2014-04-04

Review 7.  Assessing the Costs and Cost-Effectiveness of Genomic Sequencing.

Authors:  Kurt D Christensen; Dmitry Dukhovny; Uwe Siebert; Robert C Green
Journal:  J Pers Med       Date:  2015-12-10

Review 8.  Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.

Authors:  Elvira D'Andrea; Carolina Marzuillo; Corrado De Vito; Marco Di Marco; Erica Pitini; Maria Rosaria Vacchio; Paolo Villari
Journal:  Genet Med       Date:  2016-04-14       Impact factor: 8.822

9.  Epidemiology matters: peering inside the "black box" in economic evaluations of genetic testing.

Authors:  Scott D Grosse; Muin J Khoury
Journal:  Genet Med       Date:  2016-09-08       Impact factor: 8.822

10.  Utility before business.

Authors:  Steven M Teutsch; Jonathan E Fielding; Muin J Khoury; James P Evans
Journal:  Genet Med       Date:  2014-07-10       Impact factor: 8.822
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.